Historical record - last NADAC effective date: 8/22/2018
Product Information
GLYBURID-METFORMIN 1.25-250 MG is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.0529 per EA under NDC 68382065301. Its NADAC has been published 103 times since Sep 21, 2016.
FDA first approved this application on Feb 29, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1.25; 250 mg/1; mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382065301
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
8/22/2018
Active Ingredients
GLYBURIDE; METFORMIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206748FDA Approved
2/29/2016
TE Code
AB
On Market Since
4/7/2016
Pharmacological Classes
Price Statistics
The NADAC for GLYBURID-METFORMIN 1.25-250 MG has been published 103 times since Sep 21, 2016, and over the history we have for it it has declined 40.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0529 per EA |
|---|---|
| All-time high | $0.0883 (Oct 12, 2016) |
| All-time low | $0.0461 (Nov 22, 2017) |
| Median price | $0.0577 |
| Average price | $0.0548 |
| Largest weekly change | -30.0% (Oct 19, 2016) |
| Weeks tracked | 103 |
| Tracking since | Sep 21, 2016 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-40.1%
Last surveyed Sep 5, 2018 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the glyburide and metformin hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
glyburide and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GLYBURID-METFORMIN 1.25-250 MG?
The current National Average Drug Acquisition Cost (NADAC) for GLYBURID-METFORMIN 1.25-250 MG, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.0529 per EA (NDC 68382065301), effective Sep 5, 2018.
How has the price of GLYBURID-METFORMIN 1.25-250 MG changed over time?
Over the history we have for it, the NADAC for GLYBURID-METFORMIN 1.25-250 MG has declined 40.1%. It has been tracked across 103 weekly CMS publications since Sep 21, 2016.
What are the highest and lowest recorded NADAC prices for GLYBURID-METFORMIN 1.25-250 MG?
Since Sep 21, 2016, the NADAC for GLYBURID-METFORMIN 1.25-250 MG has ranged from a low of $0.0461 (Nov 22, 2017) to a high of $0.0883 (Oct 12, 2016), with a median of $0.0577 per EA.
Are there cheaper alternatives to GLYBURID-METFORMIN 1.25-250 MG?
No other NADAC-published product currently shares the active ingredient and strength of GLYBURID-METFORMIN 1.25-250 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GLYBURID-METFORMIN 1.25-250 MG?
GLYBURID-METFORMIN 1.25-250 MG (NDC 68382065301) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.